Chen Su1, Hau Yeuh Lin, Runtao Yang, Duo Xu, Michelle Lee, Natalie Pawlak, Monica Norcini, Alexandra Sideris, Esperanza Recio-Pinto, Dong Huang, Jing Wang. 1. From the Department of Anesthesiology (C.S., D.H.), Institute of Pain Medicine (D.H.), The Third Xiangya Hospital, Central South University, Changsha, China; Departments of Anesthesiology, Perioperative Care and Pain Medicine (H.Y.L., R.Y., D.X., M.L., M.N., A.S., E.R.-P., J.W.) and Neuroscience and Physiology (J.W.), New York University School of Medicine, New York, New York; and New York University (N.P.), New York, New York.
Abstract
BACKGROUND: AMPAkines augment the function of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the brain to increase excitatory outputs. These drugs are known to relieve persistent pain. However, their role in acute pain is unknown. Furthermore, a specific molecular and anatomic target for these novel analgesics remains elusive. METHODS: The authors studied the analgesic role of an AMPAkine, CX546, in a rat paw incision (PI) model of acute postoperative pain. The authors measured the effect of AMPAkines on sensory and depressive symptoms of pain using mechanical hypersensitivity and forced swim tests. The authors asked whether AMPA receptors in the nucleus accumbens (NAc), a key node in the brain's reward and pain circuitry, can be a target for AMPAkine analgesia. RESULTS: Systemic administration of CX546 (n = 13), compared with control (n = 13), reduced mechanical hypersensitivity (50% withdrawal threshold of 6.05 ± 1.30 g [mean ± SEM] vs. 0.62 ± 0.13 g), and it reduced depressive features of pain by decreasing immobility on the forced swim test in PI-treated rats (89.0 ± 15.5 vs. 156.7 ± 18.5 s). Meanwhile, CX546 delivered locally into the NAc provided pain-relieving effects in both PI (50% withdrawal threshold of 6.81 ± 1.91 vs. 0.50 ± 0.03 g; control, n = 6; CX546, n = 8) and persistent postoperative pain (spared nerve injury) models (50% withdrawal threshold of 3.85 ± 1.23 vs. 0.45 ± 0.00 g; control, n = 7; CX546, n = 11). Blocking AMPA receptors in the NAc with 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione inhibited these pain-relieving effects (50% withdrawal threshold of 7.18 ± 1.52 vs. 1.59 ± 0.66 g; n = 8 for PI groups; 10.70 ± 3.45 vs. 1.39 ± 0.88 g; n = 4 for spared nerve injury groups). CONCLUSIONS: AMPAkines relieve postoperative pain by acting through AMPA receptors in the NAc.
BACKGROUND:AMPAkines augment the function of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the brain to increase excitatory outputs. These drugs are known to relieve persistent pain. However, their role in acute pain is unknown. Furthermore, a specific molecular and anatomic target for these novel analgesics remains elusive. METHODS: The authors studied the analgesic role of an AMPAkine, CX546, in a rat paw incision (PI) model of acute postoperative pain. The authors measured the effect of AMPAkines on sensory and depressive symptoms of pain using mechanical hypersensitivity and forced swim tests. The authors asked whether AMPA receptors in the nucleus accumbens (NAc), a key node in the brain's reward and pain circuitry, can be a target for AMPAkineanalgesia. RESULTS: Systemic administration of CX546 (n = 13), compared with control (n = 13), reduced mechanical hypersensitivity (50% withdrawal threshold of 6.05 ± 1.30 g [mean ± SEM] vs. 0.62 ± 0.13 g), and it reduced depressive features of pain by decreasing immobility on the forced swim test in PI-treated rats (89.0 ± 15.5 vs. 156.7 ± 18.5 s). Meanwhile, CX546 delivered locally into the NAc provided pain-relieving effects in both PI (50% withdrawal threshold of 6.81 ± 1.91 vs. 0.50 ± 0.03 g; control, n = 6; CX546, n = 8) and persistent postoperative pain (spared nerve injury) models (50% withdrawal threshold of 3.85 ± 1.23 vs. 0.45 ± 0.00 g; control, n = 7; CX546, n = 11). Blocking AMPA receptors in the NAc with 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione inhibited these pain-relieving effects (50% withdrawal threshold of 7.18 ± 1.52 vs. 1.59 ± 0.66 g; n = 8 for PI groups; 10.70 ± 3.45 vs. 1.39 ± 0.88 g; n = 4 for spared nerve injury groups). CONCLUSIONS:AMPAkines relieve postoperative pain by acting through AMPA receptors in the NAc.
Authors: Danielle A Simmons; Christopher S Rex; Linda Palmer; Vijay Pandyarajan; Vadim Fedulov; Christine M Gall; Gary Lynch Journal: Proc Natl Acad Sci U S A Date: 2009-03-05 Impact factor: 11.205
Authors: Nina Rieckmann; Matthew M Burg; William Gerin; William F Chaplin; Lynn Clemow; Karina W Davidson Journal: Psychother Psychosom Date: 2006 Impact factor: 17.659
Authors: Paul Y Geha; Marwan N Baliki; R Norman Harden; William R Bauer; Todd B Parrish; A Vania Apkarian Journal: Neuron Date: 2008-11-26 Impact factor: 17.173
Authors: Erik Martinez; Harvey H Lin; Haocheng Zhou; Jahrane Dale; Kevin Liu; Jing Wang Journal: Front Cell Neurosci Date: 2017-05-26 Impact factor: 5.505
Authors: Haocheng Zhou; Erik Martinez; Harvey H Lin; Runtao Yang; Jahrane Antonio Dale; Kevin Liu; Dong Huang; Jing Wang Journal: Front Cell Neurosci Date: 2018-08-13 Impact factor: 6.147